Cardiac Pacemaker Market Report

Despite the importance of pacemakers in treating heart rhythm disorders, pacemakers are limited in their effectiveness and can pose risks owing to their size and dependency on wires. Cardiac resynchronization therapy is a popular treatment for the heart, which involves using carefully timed charges to bring various sections of the heart back into alignment. In existing treatments, this is accomplished using cables, which may come with their own set of issue. Even with the advancements in pacemaker technology, the transvenous implanted leads are still seen as the weak point of this therapy focused on controlling heart rhythm. The leadless permanent pacemaker system was created as an alternative to address the limitations of the transvenous method. Developments in battery technology and significant miniaturization of electronics now allow for the potential of placing the entire pacemaker system inside the right ventricle. However, this is not perfect as the best position for stimulation can vary periodically. For instance, In February 2024, University of Chicago has developed a light-powered wireless device that can be inserted into the body to control cardiovascular or neural functions. The final design company decided on features two layers of a silicon material referred to as P-type, which generates electrical charge in response to light. Nano porosity is present in the top layer, comprising numerous small holes, enhancing electrical performance by concentrating electricity and preventing its dispersion.

Additionally, AI technology can process data at a quicker speed than humans, including clinical studies, medical records, and genetic information, aiding medical professionals in making diagnoses. AI has the capability to streamline various routine tasks corresponding to record-keeping, inputting data, and analyzing scans. AI algorithms have the ability to examine current data from pacemakers, including heart rhythm patterns and physiological parameters. AI-driven pacemakers have the ability to anticipate and identify possible cardiac occurrences, like arrhythmias or worsening heart failure, before they show any clinical symptoms. The ability to detect early allows for prompt intervention and proactive control of patient well-being. For instance, In April 2024, BIOTRONIK has launched BIOMONITOR IV with SmartECG harnesses artificial intelligence (AI) and sophisticated detection algorithms to decrease 86% of incorrect alerts for all major arrhythmias, easing the workload for review and enabling healthcare providers to make prompt and precise diagnoses, allowing them to concentrate on what matters most. Such wireless pacemakers and AI-powered smart cardiac pacemaker provides ease in cardiac health drives the market expansion.

Newer alternatives to standard pacemakers include leadless pacemakers, implantable cardioverter-defibrillators (ICDs), and cardiac ablation techniques which is utilized to create scar tissue in the heart to address issues with heart rhythm. This can stop the irregular electrical signals or rhythms from traveling across your heart. By providing alternative treatment options for cardiac rhythm problems, these technologies have the potential to displace conventional pacemakers in marketing. In the realm of cardiac pacemakers, gene therapy alters cardiac cells to function like pacemaker cells, offering an alternative option to electronic pacemakers. Additionally, biological pacemakers replicate the sinoatrial node's (SAN) inherent ability to regulate heart rate by using cells or gene (Tbx18.) therapy. Biological cardiac pacemakers are a novel technique to heart rhythm management that intends to replace traditional electronic pacemakers with biological ones which highly hampers the market growth.

Apart from this, possible complications ofthe  pacemaker during the surgery or post-insertion such as infection close to the area in the heart where the device is implanted. Inflammation, discoloration or hemorrhaging in case of taking blood thinners, blood clots form in the vicinity of where the device is positioned, injury to blood vessels or nerves, lung that has collapsed, blood found in the region between the lung and the chest lining, the relocation of the device or wires may result in a heart defect. Such type of risk accompanying with the implantation of cardiac pacing device results in patient harm or discomfort and alternative treatments hampers the market growth.

Owing to rising prevalence of cardiac diseases and continuous invention in pacemaker technology drives the cardiac pacemaker market growth. For instance, in Jannuary 2024, Medtronic announced that it has obtained the CE Mark for its MicraAV2 and Micra VR2, which are the latest versions of its highly successful small, wire-free pacemakers. Micra AV2 and Micra VR2, the tiniest pacemakers globally, offer increased battery longevity and simpler programming compared to previous Micra models. They also provide the same advantages of leadless pacing, including fewer complications when compared to conventional pacemakers. Furthermore, In June 2024, Abbott was granted the CE Mark in Europe for the AVEIR dual chamber (DR) leadless pacemaker, marking a significant advancement in technology for people with abnormal heart rhythms. AVEIR DR allows for wireless communication between two leadless pacemakers, offering a unique treatment option for patients in Europe.

Rising prevalence of cardiac diseases and expanding healthcare infrastructure in North America dominate the cardiac pacemaker market. The American Heart Association (AHA), in conjunction with the National Institutes of Health, estimated that 127.9 million Americans accounting for 48.6% of ≥20 years of age have CVD, including coronary heart disease, heart failure, stroke, or hypertension. Excluding hypertension, about 28.6 million American adults (9.9%) have some type of CVD. Moreover, North America has a strong healthcare system with modern medical centers, advanced technology utilization, and a compact regulatory structure distinguished academic medical institutions and teaching hospitals leading the way in medical research, clinical trials, and specialized healthcare offerings drive the market expansion in North America.

Cardiac pacemaker market expansion in Europe is owing to the growing incidence of cardiac diseases in European people and the geriatric population. In the European Region, cardiovascular diseases are the foremost reason for disability and premature fatalities, accounting for more than 42.5% of all yearly deaths. This compares to 10,000 mortalities daily. Based on the report from WHO/Europe, males in the region have a mortality rate from CVDs that is nearly 2.5 times higher than that of females. In Eastern Europe and Central Asia, the likelihood of dying young (30-69 years) from a CVD is nearly five times greater than in western Europe, indicating a significant geographic disparity. An increase in mortality rate due to cardiovascular disease drives the cardiac pacemaker market expansion.